CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Trial Profile

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Sponsors Zhongyuan Union Stem Cell Bio-engineering Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top